iPSC-Derived Lung Epithelium Models for SARS-CoV-2 Screening
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current models for studying SARS-CoV-2 infection in the human lung lack physiological relevance and are inadequate for screening therapeutic agents effectively, as they do not replicate the complex physiology of human lung epithelial cell types and often rely on non-physiological cell lines or animal models that are not natural hosts for the virus.
Innovation Solution
Development of a system using human induced pluripotent stem cell (iPSC)-derived progenitor cells and primary cells cultured in air-liquid interface, Transwell, or microfluidic devices to model proximal and distal lung epithelium, allowing for the infection with SARS-CoV-2 and testing of therapeutic agents like remdesivir, which demonstrates strong suppression of viral replication.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Device complexity
If non-physiological cell lines or animal models are used to study SARS-CoV-2 infection, then the complexity of the model system is reduced, but the physiological relevance and accuracy of viral behavior replication deteriorates
Solution Approach 1:
The patent creates in vitro copies of human lung epithelial cells through iPSC differentiation, replicating the physiological characteristics of target cells without using complex animal models. This allows studying SARS-CoV-2 infection in a simplified system that maintains high physiological relevance through accurate cellular replication
Solution Approach 2:
The patent transforms human pluripotent stem cells into specialized lung epithelial cell types through controlled differentiation parameters. This parameter change approach generates physiologically relevant cells with specific receptor expressions (ACE2, TMPRSS2) while maintaining system simplicity compared to animal models
2Measurement precision
If complex human lung epithelial cell types are used to improve physiological relevance, then the measurement precision of viral behavior and drug response is improved, but the ease of operation and handling deteriorates
Solution Approach 1:
The patent performs preliminary differentiation of iPSCs into lung epithelial cell types before infection experiments. This advance preparation creates ready-to-use cell models with known physiological characteristics, simplifying subsequent experimental operations while maintaining high measurement precision for viral behavior studies
Solution Approach 2:
The differentiated lung epithelial cell models serve multiple functions: they can study viral entry, replication, host response, and drug effects in a single system. This multi-functionality reduces the need for multiple specialized cell types, easing operational complexity while maintaining measurement precision
Data Source
AI summary
Described herein are particular infection model systems, methods of studying infection, and method of screening compounds in various model systems. Particularly, SARS-CoV-2 is studied in these organ and infection models.